Get to know the ready-made immunity to protect against ‘RSV virus’ in children in high-risk groups.

RSV virus It is an important cause of lower respiratory tract infections In children around the world, statistics show that more than 90% of children in their first two years of life have a history of addiction.RSV virus Arrived by World Health Organization (WHO) reports that this virus is responsible for more than 60% of acute respiratory infections in children, although the majority of symptoms RSV It is not severe, similar to the common cold. But for premature babies or have a condition related to abnormalities of the lungs or heart May increase the risk of developing more severe RSV disease than other groups of children. This can cause the child to be hospitalized or even die.

Most recently, ready-made immunity protects against the RSV virus. AstraZeneca It has been approved for registration in Thailand by the Food and Drug Administration (FDA) to be used to prevent severe lower respiratory tract infections (LRTI) from the RSV virus in children with High risks include:

• Infants born prematurely (gestational age ≤ 35 weeks) and less than 6 months of age during the RSV epidemic season.
• Children under 2 years of age with chronic lung disease Bronchopulmonary Dysplasia (BPD) that required treatment in the past 6 months
• Children under 2 years of age who have congenital heart disease (CHD) that affects the blood circulation.

Related news

US monitors risk of RSV virus spreading among children

How to stay safe from ‘Influenza germs-RSV’

Check! Your child’s symptoms. Young children under 5 years old are at risk of RSV infection.

Currently, AstraZeneca’s ready-made immune system protects against RSV. Approved as an option to prevent severe lower respiratory tract infections from Respiratory Syncytial Virus or RSV1 virus in Thailand to reduce the rate of hospital admissions in high-risk children. Prepared immunizations are recommended for high-risk children once a month throughout the RSV epidemic season, with the majority of clinical studies using the drug continuously for 5 months. In Thailand Outbreaks of the RSV virus usually occur between the rainy season and winter every year.

Roman Ramos, president of AstraZeneca (Thailand), said infants in the high-risk group They are a group that is more vulnerable to severe disease and may have higher complications from the RSV virus than other children. Moreover, at present there is no specific treatment for children infected with the RSV virus. Finding methods and guidelines for Prevention is therefore a very important goal. Announcing the registration of AstraZeneca’s ready-to-use immunotherapy drug against RSV. Therefore, it is considered an important and meaningful step for high-risk infants in Thailand. Create access to prevention guidelines To reduce the risk of serious or even life-threatening effects.

Clinical study results

According to the results of the IMpact-RSV clinical study, which was conducted among premature infants or chronic lung disease at 139 research centers in the United States. United Kingdom and Canada and the results of the CHD 1 clinical study, which is a phase 3 study in a group of infants with congenital heart disease, found that ready-made immunizations preventedRSV virus of AstraZeneca It is effective in reducing the rate of hospital admissions. Including the duration of treatment and the number of days that oxygen must be received for treatment The results were consistent in the same direction for both premature infants. (born before 35 weeks of pregnancy) or have chronic lung disease and congenital heart disease After receiving 5 doses of ready-made immunity (15 mg/kg) by intramuscular injection every 30 days

The Impact-RSV study included 1,502 infants born prematurely or with chronic lung disease during the 1996-1997 RSV epidemic season. Group of infants who were born prematurely but did not have neonatal cystic fibrosis. There was a 78% reduction in hospital admissions due to RSV (8.1% vs. 1.8%), while the neonatal cystic fibrosis group had a 39% reduction (12.8% vs. 7.9%)

Moreover, the results of CHD 1 study showed that AstraZeneca’s ready-made immunization against RSV virus to infants and young children with congenital heart disease that affects the blood circulation system on a monthly basis Reduces the rate of hospital admissions due to RSV infection among high-risk children by 45%.

Ready-made immunity against RSV virus AstraZeneca It has been developed and has been in use for over 25 years and has been registered in more than 80 countries around the world, such as the United States, European Union, Canada, Korea, Japan, and Singapore, for use in the prevention of severe lower respiratory tract infections from RSV virus, for which AstraZeneca Thailand has received the right to officially import ready-made immunity in 2023.